A nurse or technician may give you testosterone as a shot directly into a muscle. Be careful about letting children or female loved ones touch the treated area or touch unwashed clothes that were in contact with the gel, as testosterone may get transferred to them. Testosterone replacement therapy comes in several forms. If you respond poorly to testosterone replacement therapy or would like to explore other options, consult your doctor. If you experience severe symptoms while on testosterone, talk to your prescribing health care provider. According to this newer research, testosterone replacement therapy may instead counteract several metabolic problems. However, a 2022 study in the journal Uro found that earlier studies may have overestimated these harmful effects. These studies together suggest that while TRT can significantly increase PSA levels, it remains within clinically acceptable ranges and does not increase the risk of prostate cancer. The supportive argument posits that by treating men with TRT, thereby increasing PSA levels and administering T to a steroid responsive cancer, a man’s risk of development of prostate cancer is significantly increased. It has been demonstrated in several trials that TRT increases serum PSA levels in some men, while androgen deprivation therapy can be used in the successful treatment of prostate cancer. While TRT for treatment of TD may cause elevations in serum PSA in some men within safe parameters (as outlined in the Endocrine Society Guidelines), it has not been definitively shown to lead to a significantly increased risk of prostate cancer Bhasin et al. 2010. The American Urology Association considers a low testosterone level in men to be anything below 300 ng/dL. A woman usually gets a testosterone test when the doctor suspects she has an abnormally high testosterone level (as opposed to a low level). Others may not have symptoms until their level is at 150 or even 100. A normal range of testosterone for men is anywhere from 300 to 1,000 nanograms per deciliter (ng/dL). Most testosterone is attached to proteins; the proteins control the amount of active testosterone in your body and prevent your tissues from using the hormone right away. A nurse or technician will draw blood from a vein in your arm and collect it in a small test tube. Especially in older men, you'll want to have your level taken in the morning because a decline is more noticeable if blood is drawn at that time. If you choose to pursue testosterone replacement therapy, it’s important to understand the common side effects you may experience. Because it involves a potent hormone, testosterone therapy carries a handful of risk factors. The FDA has approved testosterone as replacement therapy only for men who have low testosterone levels from disorders that cause hypogonadism. Women and people assigned female at birth do produce testosterone as well as estrogen, though the amounts of testosterone are much smaller than those produced by men. Testosterone replacement therapy for women It's natural for testosterone to decline as you age and not necessarily a reason for TRT. The name for the condition where you don't produce enough testosterone is hypogonadism. If testosterone is low, why not replace it? However, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. Of note, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. The Saturation Model postulates that the androgen receptors on the prostate are saturated at physiologic and even subphysiologic levels of T, such that there is minimal response of the prostatic tissue to TRT. Only seven men throughout the study were found to have PSA levels above 4.0 ng/ml, six of whom were treated for suspected prostatitis with a resultant interval decrease in PSA. One hundred and sixty-one men completed the 1-year study and 115 entered into a 5-year study extension; 51 men completed the sixth year of the study and reported a statistically significant increase from a mean baseline of 0.50 ng/ml to a mean level of 0.80 ng/ml (95% CI 0.19–0.41). To date, there are no prospective studies that have evaluated the risk of VTE in men receiving exogenous T supplementation. Similarly, a prospective, population-based study of 1350 men aged 50–84 years yielded only 4.5 VTE events per 1000 person-years over 10.4 years of follow up with an insignificant HR of 1.06 (95% CI 0.83–1.35) Svartberg et al. 2009. Additionally, the authors admit that they were unable to explore whether or not the increase in CVD mortality was directly related to serum T levels or baseline TD. A limitation of this study centers on utilization of a healthcare database that did not include information on either serologic or diagnostic criteria for men who received TRT.
